−1.02USD
−57.557MUSD
7.445M
About Neoleukin Therapeutics, Inc.
Sector
Industry
CEO
Donna M. Cochener-Metcalfe
Website
Headquarters
Seattle
Employees (FY)
56
Founded
2003
ISIN
US64049K2033
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
NLTX 16.00 target, if 13.43 resistance can be overcome13.43 is next major resistance (local high) to overcome, then targeting 16.
Support for idea
+breakout ascending triangle (12 resistance)
+local support/resistance (12.00, 13.43, 16.00)
+wave 3 wyckoff (8>12 | 12>10 | 10>+)
+inverse head-and-shoulders
NLTX - DAILY CHART Hi, today we are going to talk about Neoleukin Therapeutics and its current landscape.
Neoleukin Therapeutics company receives attention today as the Cancer - Drug Race heats up, in the middle a day of the announcements of a $5.2 billion total in Acquisitions by big names of the pharmaceuticals s
NLTX - Perfect Retracement - Can It Go On?Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. It
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
